REACH

This study is an international prospective observational registry of subjects at increased risk of atherothrombotic events, coordinated in Australia by CCRE Therapeutics together with the Baker Heart Research Institute.

The objectives of the study are to evaluate the long-term risk (yearly event rate) of atherothrombotic events globally, as well as in different population subgroups, compare outcomes within different subject profiles and define predictors of risk for subsequent events.  In separate substudies, data collected for the Australian cohort will provide information on the prevalence of peripheral artery disease (PAD) and provide estimates on the economic cost of clinical atherothrombosis.  The study will also enhance the quality of primary and secondary cardiovascular prevention among Australian general practitioners.  The enrolment phase of the study was completed in July 2004 and recruited 2877 participants across Australia and over 50,000 patients worldwide, who will be followed-up for a period of 24 months.